<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="w">
		<monograph id="1" status="active" ha="yes">
			<mono_name> warfarin (Rx)</mono_name>
			<info>
				<pronunciation>(war′far-in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x231">Coumadin</tradename>
					<tradename id="tnidelem4x230">Jantoven</tradename>
				</tradenames>
				<class type="func"> Anticoagulant</class>
				<class type="chem"> Coumarin derivative</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="confusion" id="sidelem4x33">
				<para>
					<confusion>
						<tradename id="tnidelem4x330">Coumadin</tradename>
						<drug type="generic" refid="idelem4x330">Cardura/Compazine</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x37">
				<sec_title>Action:</sec_title>
				<para>Interferes with blood clotting by indirect means; depresses hepatic synthesis of vit-K–dependent coagulation factors (II, VII, IX, X)</para>
			</section>
			<section type="uses" id="sidelem4x42">
				<sec_title>Uses:</sec_title>
				<para>Antiphospholipid antibody syndrome, arterial thromboembolism prophylaxis, DVT, MI prophylaxis, after MI, stroke prophylaxis, thrombosis prophylaxis</para>
				<section type="none" id="sidelem4x47">
					<section type="none" id="sidelem4x48">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Angina, unstable angina</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x53">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, hypersensitivity, hemophilia, leukemia with bleeding, peptic ulcer disease, thrombocytopenic purpura, hepatic disease (severe), malignant hypertension, subacute bacterial endocarditis, acute nephritis, blood dyscrasias, eclampsia, preeclampsia, hemorrhagic tendencies; surgery of CNS, eye; traumatric surgery with large open surface, bleeding tendencies of GI/GU/respiratory tract, stroke, aneurysms, pericardial effusion, spinal puncture, major regional/lumbar block anesthesia</para>
				<para>
					<bbw>Bleeding</bbw>
				</para>
				<section type="none" id="sidelem4x68">
					<section type="none" id="sidelem4x69">
						<sec_title>Precautions:</sec_title>
						<para> Geriatric patients, alcoholism, CHF, debilitated patients, trauma, indwelling catheters, severe hypertension, active infections, protein C deficiency, polycythemia vera, vasculitis, severe diabetes, Asian patients (CYP2C9), protein C, S deficiency</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x74">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x82">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x82">
							<item>
								<label>•</label>
								<para> 2-10 mg/day × 2-4 days, then titrated to INR/PT</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x89">
					<label>•</label>
					<sec_title>Adolescent/child/infant<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x89">
							<item>
								<label>•</label>
								<para> 0.2 mg/kg/day × 2 days titrated to INR</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x93">
					<section type="none" id="sidelem4x94">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x99">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x102">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x106">
									<item>
										<label>•</label>
										<para>At same time each day to maintain steady blood levels without regard to food; food decreases rate but not extent of absorption; do not change brands</para>
									</item>
									<item>
										<label>•</label>
										<para>Tabs whole or crushed</para>
									</item>
									<item>
										<label>•</label>
										<para>Avoiding all IM inj that may cause bleeding</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in tight container</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x127">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x130">
					<section type="none" id="sidelem4x131">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Fever,</emphasis> dizziness, fatigue, headache, lethargy</para>
					</section>
					<section type="none" id="sidelem4x139">
						<sec_title>CV:</sec_title>
						<para> Angina, chest pain, edema, hypotension, syncope</para>
					</section>
					<section type="none" id="sidelem4x144">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea,</emphasis> nausea, vomiting, anorexia, stomatitis, cramps, <emphasis style="bold">hepatitis,</emphasis> cholestatic jaundice</para>
					</section>
					<section type="none" id="sidelem4x155">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Hematuria</emphasis></para>
					</section>
					<section type="none" id="sidelem4x162">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Hemorrhage, agranulocytosis, leukopenia, eosinophilia,</emphasis> anemia, ecchymosis, petechiae</para>
					</section>
					<section type="none" id="sidelem4x170">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> dermatitis, urticaria, alopecia, pruritus</para>
					</section>
					<section type="none" id="sidelem4x178">
						<sec_title>MISC:</sec_title>
						<para> Epistaxis, hemoptysis, mouth ulcers, taste disturbances, priapism, dyspnea</para>
					</section>
					<section type="none" id="sidelem4x183">
						<sec_title>MS:</sec_title>
						<para> Bone fractures</para>
					</section>
					<section type="none" id="sidelem4x188">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis,</emphasis> coma, cholesterol, microembolism, <emphasis style="bold">exfoliative dermatitis, purple toe syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x198">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x201">
					<section type="none" id="sidelem4x202">
						<sec_title>PO:</sec_title>
						<para> Onset 12-24 hr, peak 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-4 days, duration 3-5 days, effective half-life 20-60 hr; metabolized in liver; excreted in urine, feces (active/inactive metabolites); crosses placenta, 99% bound to plasma proteins</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x213">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> warfarin action—allopurinol, amiodarone, chloral hydrate, chloramphenicol, cimetidine, clofibrate, cotrimoxazole, COX-2 selective inhibitors, dextrothyroxine, diflunisal, disulfiram, erythromycin, ethacrynic acids, furosemide, glucagon, heparin, HMG-CoA reductase inhibitors, indomethacin, isoniazid, mefenamic acid, metroNIDAZOLE, mifepristone, NSAIDs, oxyphenbutazones, penicillins, phenylbutazone, quiNIDine, quinolone antiinfectives, RU-486, salicylates, sulfinpyrazone, sulfonamides, sulindac, SSRIs, steroids, thrombolytics, thyroid, tricyclics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—oral sulfonylureas, phenytoin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> warfarin action—aprepitant, azaTHIOprine, barbiturates, bile acid sequestrants, bosentan, carBAMazepine, dicloxacillin, estrogens, ethchlorvynol, factor IX/VIIa, griseofulvin, nafcillin, oral contraceptives, phenytoin, rifampin, sucralfate, sulfaSALAzine, thyroid, vit K, vit K foods</para>
				<section type="none" id="sidelem4x228">
					<section type="none" id="sidelem4x229">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> risk for bleeding—angelica, anise, basil, chamomile, chondroitin, dong quai, evening primrose, feverfew, garlic, ginger, ginkgo, ginseng, horse chestnut, kava, licorice, melatonin, red yeast rice, saw palmetto</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> anticoagulant effect—coenzyme Q10, St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x240">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> T<emphasis style="inf">3</emphasis> uptake, LFTs</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> uric acid</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x254">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x257">
					<section type="none" id="sidelem4x258">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Blood studies (Hct, PT, platelets, occult blood in stools) q3mo; INR: in hospital daily after 2nd or 3rd dose; when in therapeutic range for 2 consecutive days, monitor 2-3× wk for 1-2 wk, then less frequently, depending on stability of INR results; Outpatient: monitor every few days until stable dose then periodically thereafter, depending on stability of INR results, usually at least monthly</bbw>
						</para>
						<para>
							<bbw>Bleeding gums, petechiae, ecchymosis, black tarry stools, hematuria; fatal hemorrhage can occur</bbw>
						</para>
						<para>
							<emphasis alert="nurse">Fever, skin rash, urticaria</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x286">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x290">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in deep venous thrombosis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x296">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x300">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations that may cause serious product interactions unless directed by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry emergency ID identifying product taken</para>
								</item>
								<item>
									<label>•</label>
									<para>About the importance of compliance</para>
								</item>
								<item>
									<label>•</label>
									<para>To report any signs of bleeding: gums, under skin, urine, stools; to use soft-bristle toothbrush to avoid bleeding gums; to use electric razor</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid hazardous activities (e.g., football, hockey, skiing), dangerous work</para>
								</item>
								<item>
									<label>•</label>
									<para>About the importance of avoiding unusual changes in vitamin intake, diet, or lifestyle</para>
								</item>
								<item>
									<label>•</label>
									<para>To inform all health care providers of anticoagulant intake</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
</alpha>
</drug_guide>